Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Zillow, Seagate upgrades among today's top calls on Wall Street » 10:31
08/04/20
08/04
10:31
08/04/20
10:31
Z

Zillow

$69.55 /

+1.58 (+2.32%)

, ZG

Zillow

$69.26 /

+1.51 (+2.23%)

, STX

Seagate

$45.53 /

+0.79 (+1.77%)

, MCK

McKesson

$157.58 /

-2.2 (-1.38%)

, TTWO

Take-Two

$173.27 /

+5.26 (+3.13%)

, NKTX

Nkarta

$30.24 /

+3.97 (+15.11%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
ZG Zillow
$69.26 /

+1.51 (+2.23%)

Z Zillow
$69.55 /

+1.58 (+2.32%)

TTWO Take-Two
$173.27 /

+5.26 (+3.13%)

STX Seagate
$45.53 /

+0.79 (+1.77%)

NKTX Nkarta
$30.24 /

+3.97 (+15.11%)

MCK McKesson
$157.58 /

-2.2 (-1.38%)

Z Zillow
$69.55 /

+1.58 (+2.32%)

08/04/20 Susquehanna
Zillow upgraded to Neutral on improving real estate market at Susquehanna
08/03/20 Standpoint Research
Zillow downgraded to Hold from Buy at Standpoint Research
05/06/20 Needham
Needham says checks indicate Zillow discounted May Premier Agent by 20%-50%
04/20/20 Stephens
Stephens ups CoreLogic, downgrades two others in real estate services shake-up
ZG Zillow
$69.26 /

+1.51 (+2.23%)

08/04/20 Susquehanna
Zillow upgraded to Neutral from Negative at Susquehanna
07/20/20 Goldman Sachs
Zillow price target raised to $58 from $47 at Goldman Sachs
07/17/20 JMP Securities
Zillow price target raised to $75 from $60 at JMP Securities
STX Seagate
$45.53 /

+0.79 (+1.77%)

08/04/20
Fly Intel: Top five analyst upgrades
08/04/20 UBS
Seagate upgraded to Neutral from Sell at UBS
08/03/20 Stifel
Western Digital to benefit from data center strength, says Stifel
07/29/20
Fly Intel: Top five analyst downgrades
MCK McKesson
$157.58 /

-2.2 (-1.38%)

08/04/20 JPMorgan
McKesson price target raised to $198 from $187 at JPMorgan
08/04/20 Deutsche Bank
Deutsche Bank upgrades McKesson to Buy after 'solid' Q1 beat
08/04/20 Deutsche Bank
McKesson upgraded to Buy from Hold at Deutsche Bank
TTWO Take-Two
$173.27 /

+5.26 (+3.13%)

08/04/20
Fly Intel: Top five analyst downgrades
08/04/20 MKM Partners
Take-Two price target raised to $190 from $165 at MKM Partners
08/04/20 Wedbush
Take-Two price target raised to $210 from $170 at Wedbush
08/04/20 Oppenheimer
Take-Two price target raised to $190 from $155 at Oppenheimer
NKTX Nkarta
$30.24 /

+3.97 (+15.11%)

08/04/20 Mizuho
Mizuho starts Nkarta with Buy rating, $34 price target
08/04/20 Evercore ISI
Nkarta initiated with an Outperform at Evercore ISI
08/04/20 Stifel
Nkarta initiated with a Buy at Stifel
08/04/20 Mizuho
Nkarta initiated with a Buy at Mizuho
ZG Zillow
$69.26 /

+1.51 (+2.23%)

Z Zillow
$69.55 /

+1.58 (+2.32%)

TTWO Take-Two
$173.27 /

+5.26 (+3.13%)

STX Seagate
$45.53 /

+0.79 (+1.77%)

MCK McKesson
$157.58 /

-2.2 (-1.38%)

  • 10
    Jul
  • 13
    May
TTWO Take-Two
$173.27 /

+5.26 (+3.13%)

STX Seagate
$45.53 /

+0.79 (+1.77%)

MCK McKesson
$157.58 /

-2.2 (-1.38%)

ZG Zillow
$69.26 /

+1.51 (+2.23%)

Z Zillow
$69.55 /

+1.58 (+2.32%)

TTWO Take-Two
$173.27 /

+5.26 (+3.13%)

STX Seagate
$45.53 /

+0.79 (+1.77%)

NKTX Nkarta
$30.24 /

+3.97 (+15.11%)

MCK McKesson
$157.58 /

-2.2 (-1.38%)

Z Zillow
$69.55 /

+1.58 (+2.32%)

TTWO Take-Two
$173.27 /

+5.26 (+3.13%)

STX Seagate
$45.53 /

+0.79 (+1.77%)

MCK McKesson
$157.58 /

-2.2 (-1.38%)

Initiation
Mizuho starts Nkarta with Buy rating, $34 price target » 07:06
08/04/20
08/04
07:06
08/04/20
07:06
NKTX

Nkarta

$26.27 /

+0.42 (+1.62%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed initiated coverage of Nkarta with a Buy rating and $34 price target. The analyst believes natural killer cell biology is "naturally much more elegant than T cell biology." NK cells express a wide variety of inhibitory receptors that identify healthy normal cells, and activating receptors that recognize diseased cells, Syed tells investors in a research note. The analyst points out that Nkarta is developing allogeneic engineered NK cell based therapies to treat cancer.

ShowHide Related Items >><<
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

08/04/20 Evercore ISI
Nkarta initiated with an Outperform at Evercore ISI
08/04/20 Stifel
Nkarta initiated with a Buy at Stifel
08/04/20 Mizuho
Nkarta initiated with a Buy at Mizuho
08/04/20 Cowen
Nkarta initiated with an Outperform at Cowen
  • 10
    Jul
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

Initiation
Nkarta initiated with an Outperform at Evercore ISI » 06:43
08/04/20
08/04
06:43
08/04/20
06:43
NKTX

Nkarta

$26.27 /

+0.42 (+1.62%)

Evercore ISI initiated…

Evercore ISI initiated coverage of Nkarta with an Outperform rating and $55 price target.

ShowHide Related Items >><<
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

08/04/20 Stifel
Nkarta initiated with a Buy at Stifel
08/04/20 Mizuho
Nkarta initiated with a Buy at Mizuho
08/04/20 Cowen
Nkarta initiated with an Outperform at Cowen
  • 10
    Jul
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

Initiation
Nkarta initiated with a Buy at Stifel » 06:28
08/04/20
08/04
06:28
08/04/20
06:28
NKTX

Nkarta

$26.27 /

+0.42 (+1.62%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey initiated coverage of Nkarta with a Buy rating and $41 price target. The company's natural killer, or NK, cell engineering platform overcomes the historical challenges associated with ex-vivo NK cell manipulation, said Willey, who sees harnessing NK cells as "the next significant chapter in the generation of engineered cell-based therapies to treat cancer." However, he acknowledges longer-term data will ultimately be needed to discern any meaningful differences in competing platform technologies.

ShowHide Related Items >><<
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

08/04/20 Mizuho
Nkarta initiated with a Buy at Mizuho
08/04/20 Cowen
Nkarta initiated with an Outperform at Cowen
  • 10
    Jul
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

Initiation
Nkarta initiated with a Buy at Mizuho » 06:18
08/04/20
08/04
06:18
08/04/20
06:18
NKTX

Nkarta

$26.27 /

+0.42 (+1.62%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed initiated coverage of Nkarta with a Buy rating and $34 price target.

ShowHide Related Items >><<
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

08/04/20 Cowen
Nkarta initiated with an Outperform at Cowen
  • 10
    Jul
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

Initiation
Nkarta initiated with an Outperform at Cowen » 06:17
08/04/20
08/04
06:17
08/04/20
06:17
NKTX

Nkarta

$26.27 /

+0.42 (+1.62%)

Cowen initiated coverage…

Cowen initiated coverage of Nkarta with an Outperform rating.

ShowHide Related Items >><<
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

  • 10
    Jul
NKTX Nkarta
$26.27 /

+0.42 (+1.62%)

Over a week ago
Initiation
Dun & Bradstreet initiated with a Neutral at Citi » 06:32
07/28/20
07/28
06:32
07/28/20
06:32
DNB

Dun & Bradstreet

$25.30 /

+0.1 (+0.40%)

Citi analyst Peter…

Citi analyst Peter Christiansen initiated coverage of Dun & Bradstreet with a Neutral rating and $28 price target. The analyst believes current stock levels are pricing in a "faster turnaround with no major hiccups along away." He expects Dun & Bradstreet's turnaround efforts to "gradually materialize" over the next few years, allowing investors to "wait and see more proof points."

ShowHide Related Items >><<
DNB Dun & Bradstreet
$25.30 /

+0.1 (+0.40%)

07/27/20 JPMorgan
Dun & Bradstreet initiated with a Neutral at JPMorgan
07/27/20 Wells Fargo
Dun & Bradstreet initiated with an Equal Weight at Wells Fargo
07/27/20 Deutsche Bank
Dun & Bradstreet initiated with a Buy at Deutsche Bank
07/27/20 BofA
Dun & Bradstreet initiated with a Buy at BofA
  • 01
    Jul
DNB Dun & Bradstreet
$25.30 /

+0.1 (+0.40%)

DNB Dun & Bradstreet
$25.30 /

+0.1 (+0.40%)

Initiation
Accolade initiated with an Outperform at Baird » 13:52
07/27/20
07/27
13:52
07/27/20
13:52
ACCD

Accolade

$33.98 /

+1.01 (+3.06%)

Baird analyst Matthew…

Baird analyst Matthew Gillmor initiated coverage of Accolade with an Outperform rating and $40 price target. The company, whose tech-enabled platform integrates health/benefit offerings and drives "differentiated results for employer clients," is in the early stages of redefining the healthcare member navigation experience, Gillmor contends. He sees Accolade having a large market opportunity and "highly visible" path to greater than 20% annual growth.

ShowHide Related Items >><<
ACCD Accolade
$33.98 /

+1.01 (+3.06%)

07/27/20
Fly Intel: Top five analyst initiations
07/27/20 SVB Leerink
Accolade initiated with a Market Perform at SVB Leerink
07/27/20 BofA
Accolade initiated with a Buy at BofA
07/27/20 Morgan Stanley
Accolade initiated with an Overweight at Morgan Stanley
  • 02
    Jul
ACCD Accolade
$33.98 /

+1.01 (+3.06%)

Initiation
Fly Intel: Top five analyst initiations » 10:17
07/27/20
07/27
10:17
07/27/20
10:17
IMTX

Immatics

$11.00 /

+0.5 (+4.76%)

, STSA

Satsuma Pharmaceuticals

$26.44 /

+0.94 (+3.69%)

, OSK

Oshkosh

$79.89 /

+1.435 (+1.83%)

, LMND

Lemonade

$71.74 /

-6.32 (-8.10%)

, ACCD

Accolade

$33.05 /

+0.08 (+0.24%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immatics (IMTX) initiated with an Outperform at SVB Leerink. 2. Satsuma Pharmaceuticals (STSA) initiated with a Buy at H.C. Wainwright. 3. Oshkosh (OSK) initiated with an Outperform at Raymond James. 4. Lemonade (LMND) was initiated with an Outperform at JMP Securities, a Market Perform at William Blair, a Perform at Oppenheimer, an Equal Weight at Barclays and Morgan Stanley, and a Sell at Goldman Sachs. 5. Accolade (ACCD) initiated with a Buy at Goldman Sachs and BofA, an Overweight at Morgan Stanley and Piper Sandler, a Market Perform at SVB Leerinkm, and a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
STSA Satsuma Pharmaceuticals
$26.44 /

+0.94 (+3.69%)

OSK Oshkosh
$79.89 /

+1.435 (+1.83%)

LMND Lemonade
$71.74 /

-6.32 (-8.10%)

IMTX Immatics
$11.00 /

+0.5 (+4.76%)

IMTX Immatics
$11.00 /

+0.5 (+4.76%)

07/27/20 SVB Leerink
SVB Leerink bullish on Immatics, initiates with an Outperform
07/27/20 SVB Leerink
Immatics initiated with an Outperform at SVB Leerink
07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Jefferies
Jefferies starts Immatics at Buy with $14 price target
STSA Satsuma Pharmaceuticals
$26.44 /

+0.94 (+3.69%)

07/27/20 H.C. Wainwright
Satsuma Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/11/20 SVB Leerink
Satsuma Pharmaceuticals price target raised to $35 from $20 at SVB Leerink
03/02/20 Credit Suisse
Satsuma Pharmaceuticals price target raised to $32 from $20 at Credit Suisse
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
OSK Oshkosh
$79.89 /

+1.435 (+1.83%)

07/27/20 Raymond James
Oshkosh initiated with an Outperform at Raymond James
07/27/20 Raymond James
Oshkosh initiated with an Outperform at Raymond James
07/01/20 Deutsche Bank
Oshkosh resumed with a Buy at Deutsche Bank
06/04/20
Fly Intel: Top five analyst upgrades
LMND Lemonade
$71.74 /

-6.32 (-8.10%)

07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
07/27/20 Barclays
Lemonade initiated with an Equal Weight at Barclays
07/27/20 JMP Securities
Lemonade initiated with an Outperform at JMP Securities
ACCD Accolade
$33.05 /

+0.08 (+0.24%)

07/27/20 SVB Leerink
Accolade initiated with a Market Perform at SVB Leerink
07/27/20 BofA
Accolade initiated with a Buy at BofA
07/27/20 Morgan Stanley
Accolade initiated with an Overweight at Morgan Stanley
07/27/20 BofA
Accolade initiated with a Buy at BofA
STSA Satsuma Pharmaceuticals
$26.44 /

+0.94 (+3.69%)

OSK Oshkosh
$79.89 /

+1.435 (+1.83%)

  • 02
    Jul
  • 02
    Jul
  • 13
    Sep
OSK Oshkosh
$79.89 /

+1.435 (+1.83%)

LMND Lemonade
$71.74 /

-6.32 (-8.10%)

LMND Lemonade
$71.74 /

-6.32 (-8.10%)

Initiation
Accolade initiated with a Market Perform at SVB Leerink » 09:31
07/27/20
07/27
09:31
07/27/20
09:31
ACCD

Accolade

$32.97 /

+0.63 (+1.95%)

As previously reported,…

As previously reported, SVB Leerink analyst Stephanie Davis initiated coverage of Accolade with a Market Perform rating and $34 price target. The analyst notes that Accolade operates as a healthcare navigation and benefits management platform, helping client members navigate and optimize their care journey. Davis believes the growing cohort of employee-benefits facing names within the health tech universe solidifies the long-term need for Accolade's care navigation platform, although she acknowledges the growth trajectory is not without near-term risk due to pandemic headwinds. While the analyst fundamentally likes the story, with shares rallying nearly 50% since coming public she sees only modest upside from current levels.

ShowHide Related Items >><<
ACCD Accolade
$32.97 /

+0.63 (+1.95%)

07/27/20 BofA
Accolade initiated with a Buy at BofA
07/27/20 Morgan Stanley
Accolade initiated with an Overweight at Morgan Stanley
07/27/20 BofA
Accolade initiated with a Buy at BofA
07/27/20 Credit Suisse
Accolade initiated with a Neutral at Credit Suisse
  • 02
    Jul
ACCD Accolade
$32.97 /

+0.63 (+1.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.